Form 4: Globus Medical CEO Pfeil Receives 100,000 Stock Options
Insider Transaction Report
Globus Medical's President and CEO, Keith W. Pfeil, was granted 100,000 stock options with an exercise price of $94.15, vesting over four years.
Summary
- Keith W. Pfeil, President and CEO of Globus Medical Inc. (GMED), was granted 100,000 stock options.
- The stock options have an exercise price of $94.15 per share.
- The grant date for these options was January 21, 2026, and they are set to expire on January 21, 2036.
- The options will vest over a four-year period, with 25% (25,000 options) vesting on January 1, 2027, and the remaining 75% vesting monthly (1/48th of the total) thereafter.
Sentiment
Score: 7
Explanation: The grant of stock options to the President and CEO is a positive event as it aligns management's long-term interests with shareholder value creation, incentivizing performance over a four-year vesting period.
Positives
- The grant of stock options to the President and CEO aligns management's long-term interests with shareholder value creation.
- The four-year vesting schedule incentivizes sustained performance and commitment from the executive.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction.
Industry Context
The grant of stock options is a common form of executive compensation in the medical device industry, designed to attract, retain, and motivate key leadership by linking their financial incentives to the company's long-term stock performance.
Comparison to Industry Standards
- This type of equity grant is a standard component of executive compensation packages across the medical technology sector, comparable to practices at companies like Stryker, Zimmer Biomet, or Medtronic, which also utilize stock options to align executive interests with shareholder returns.
Stakeholder Impact
- Shareholders may benefit from the increased alignment of executive incentives with long-term company performance and stock appreciation.
- Employees may view this as a positive sign of executive commitment and stability within the company.
Next Steps
- Continued vesting of the granted stock options according to the established schedule.
Key Dates
| Date | Description |
|---|---|
| 01/21/2026 | Date of earliest transaction (stock option grant date). |
| 01/01/2027 | First vesting date for 1/4 of the granted options. |
| 01/21/2036 | Expiration date of the stock options. |
Keywords
Globus Medical, GMED, Stock Options, Executive Compensation, Insider Transaction, Form 4, Keith W. Pfeil
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.